Kilitch Drugs (India) Limited
KILITCH.NS·NSE·Healthcare
208.47−0.44 (−0.21%)today
At close: Nov 5, 3:29 PM IST · May be delayed up to 15 min · INR
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close208.91
Open211.00
Day range206.65211.28
52-week range117.25267.90
Off day high−1.33%
Off 52-week high−22.18%
Volume30.57K
Avg. volume (3M)57.98K
Market cap7.29B
EPS (TTM)8.80
Forward P/E13.63
P/E ratio (TTM)23.69
Dividend yield—
Beta (5Y)0.34
Shares outstanding34.96M
Short interest—
Earnings dateAug 6, 2025 (est.)
Analyst target—
Profit margin12.67%
Against its peers
Compare in full ›| KILITCH.NS | IOLCP.BO | THEMISMED.BO | 300705.SZ | JENBURPH.BO | KPL.BO | |
|---|---|---|---|---|---|---|
| Market cap | 7.29B | 55.54B | 9.36B | 5.33B | 4.18B | 38.50B |
| P/E (TTM) | 23.7 | 27.3 | 23.5 | 16.9 | 12.7 | 47.5 |
| Forward P/E | 13.6 | 17.5 | — | 7.6 | 27.2 | — |
| Price/book | 2.6 | 2.9 | 2.4 | 2.7 | 2.1 | 11.6 |
| Dividend yield | — | 0.54% | 0.50% | 3.81% | 2.30% | — |
| 1-year change | +10.83% | +102.42% | −15.42% | −36.07% | −23.57% | +317.61% |
| Today | −0.21% | +3.08% | +1.22% | +1.43% | +1.83% | −0.92% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All KILITCH.NS news ›Kilitch Drugs (India) Limited (KILITCH) share price
₹218.98 on NSE as of 2026-10-19. -4.96% on the day. market cap ₹766 Cr. P/E 17.5. 52-week range ₹124.45 to ₹260.70. Healthcare. Kilitch Drugs makes medicines in Mumbai and in Ethiopia, and sells most of them abroad. This report covers the…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
3mentions in 30 days
3with it in the headline
Negativesentiment
Mentioned with
People in the coverage
Most coverage from
- univest.in2
- t.co1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.